Mezzion Pharma Co. Ltd., of Seoul, South Korea, said it signed a deal with New England Research Institutes Inc., which is authorized by the National Heart, Lung and Blood Institute (NHLBI)-supported Pediatric Heart Network to manage and conduct clinical trials.